Simcere Teams Up Again With Bristol-Myers For Co-Development In China
This article was originally published in The Pink Sheet Daily
Executive Summary
After signing a deal in deal in November 2010 for a MET-VEGFR-2 inhibitor, Simcere and BMS switch gears for a CETP inhibitor.
You may also be interested in...
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.
Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds
Phase II Preview For Roche's Dalcetrapib May Give CETP Inhibition A Boost
European Society of Cardiology Congress abstract for small study suggests Roche's dalcetrapib is safe and works on plaque burden.